Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

NCT03805022 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

351

Enrollment

OTHER

Sponsor class

Conditions

Non-metastatic Soft-tissue Sarcoma
Resectable

Interventions

DRUG: Doxorubicin
DRUG: Ifosfamide or dacarbazine
DRUG: Doxorubicin
DRUG: Ifosfamide or dacarbazine
DRUG: At the discretion of the investigator

Sponsor

Institut Bergonié

Collaborators

[object Object]
[object Object]